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KEY INSIGHTS 
1. A blockbuster drug suffers a patent cliff and has
to contend with aggressive competition from
generics in a heavily regulated, price-driven
market.
2. Significant differences in terms of in-market
distribution and logistics do not exist between
the branded and generic drugs. Differentiation
borders more on commercial strategies.
3. By virtue of the existing legal dispensation the
pharmacist is the decision maker in terms of
which drug to dispense and subsequently has
power to shape demand.
Introduction 
Global Pharmaceuticals and Medicine Manufacturing 
has experienced steady growth over the past five 
years to 2012 (IBISWorld, 2013). This growth 
notwithstanding, the recent economic downturn has 
necessitated austerity measures by governments 
and health insurance companies to cut cost, hence 
the mounting price pressures on the pharmaceutical 
companies. Moreover, patent expirations on 
blockbuster drugs, fierce competition from generics 
and decreasing R&D productivity, not to mention 
drug counterfeiting and litigation costs, are equally 
formidable challenges confronting the branded 
pharmaceutical companies  
Hitherto, patent protection ensured that 
pharmaceutical companies encountered minimal 
competition for blockbuster drugs that allowed the 
pharmaceutical companies to maintain high price 
points and margins. Of the 20 highest-grossing drugs 
today, 18 will be stripped of their patent protection 
before 2015; Lipitor, Plavix and Nexium would seem 
to be the hardest hit. According to Ehrhardt et.al 
(2012), drugs worth US$ 400 billion in revenue will 
be open to generic competition by 2015. This 
unrelenting competition has been heightened by 
heavy industry regulations (bordering particularly on 
pricing) and policy adjustments by governments all 
over the world to curtail escalating healthcare 
spending. The effect of the loss of exclusivity on 
sales of four of the biggest-selling drugs is shown 
below. 
To survive this aggressive competition, many key 
players have adopted new strategies and business 
models including improving R&D productivity through 
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cost cutting measures and partnerships with 
academic institutions to enhance innovative 
research. Others have resorted to mergers and 
acquisitions, consolidation of product portfolios and a 
gradual shift to consumer healthcare segment which 
have minimal regulatory controls and R&D costs. 
This thesis seeks to explore other ways by which the 
pharmaceutical companies could contain the 
situation and remain competitive by focusing on the 
supply chain. Specifically, it will delve into different 
approaches to supply chain in the pharmaceutical 
industry with particular emphasis on in-market 
distribution and logistics, whilst taking due 
cognizance of existing regulatory frameworks. 
 
Methodology 
The main focus of this research is to learn about the 
best practices, innovative ideas and efficiencies of 
the in-market distribution in Spain of the drug in this 
study, and its similar drugs (generics).  
Relevant Literature Review 
Relevant publicly available data was used to assess 
the current state of the pharmaceutical industry and 
to better appreciate future global trends in terms of 
spending, R&D and emerging markets. Additionally, 
the branded and generics pharmaceutical supply 
chain was assessed to obtain an overview of general 
processes, products, performances and strategies.  
Data collection 
To obtain the necessary data, field interviews were 
conducted with key stakeholders, including the 
sponsor company, wholesalers, pharmacies and 
industry experts. The objective was to understand 
the distribution channels of the drug under study, 
competitor’s and stakeholder’s strategies and why 
they adopted those strategies. Industry experts were 
interviewed to help clarify issues, shed light on best 
practices and strategies and to advance their 
opinions on future trends. 
The Spanish pharmaceutical distribution landscape is 
shown below; 
 
Data analyses 
The data obtained was largely qualitative. For this 
reason, comparisons among strategies could only be 
performed on a qualitative basis.  
The comparisons enabled us to decipher and 
elaborate on best market practices and also to 
advance recommendations. It was however, not 
possible to quantify the possible impact of the 
recommended strategies. 
Recommendations 
There were not major differences between the 
branded and generic drug manufacturers in terms of 
in-market distribution. The decision by wholesalers 
and pharmacies about which manufacturer to engage 
with are more commercially driven and profitability 
seems to be the driving force. It may therefore, be 
helpful to consider trading the existing high service 
levels with appealing discounts without causing 
major service inconveniences. 
By virtue of the existing legal dispensation, 
pharmacies wield considerable power in shaping 
demand whilst the greater volume of purchases is 
through the wholesale channel. Fostering closer 
relationships with these actors in the areas of 
continuous education and training will prove helpful.  
Pharmacies are not bound by a minimum order 
quantity but rather minimum order value when they 
place an order directly to the manufacturer. They 
could be served directly at the pharmacy or via 
transfer orders through the wholesalers. These 
notwithstanding, the pharmacies, wholesalers and 
manufacturers perform forecasting separately, 
independent of one another which may affect the 
overall quality of demand forecasts. This affords 
scope for collaboration in terms of information 
sharing. The manufacturer could agree to a fee for 
the distributor for the latter’s role in maintaining a 
certain inventory cap of the drug and agreed service 
levels. The distributor or pharmacy will intend 
communicate its inventory levels with the 
manufacturer at agreed time frames. The 
manufacturer could also agree to share any 
additional supply chain gains with all parties 
according to pre-agreed criteria. This win-win 
situation helps avoid speculative buying or ordering 
by the wholesaler/pharmacies. This ensures some 
steady income stream for them. For the 
manufacturer, the inventory level information it 
receives enables it to properly forecast demand and 
the agreed inventory cap assures a constant 
availability of its products. Finally, this arrangement 
could help build the much needed trust among the 
parties and enable the manufacturer to easily 
collaborate with pharmacies in activities including 
promotions or drug awareness creation. 
It is also recommended that, while production and 
distribution of medicines are organized in different 
business units, sales force should be centralized.  
Some of the pharmacy reps interviewed explained 
that they would prefer to deal with one assigned 
sales representative, rather than one representative 
for each type of medicine. It seems counterintuitive to 
place different orders to the same company, based 
on the type of medicine. This would improve the 
relationship and negotiations.  
Further Research 
The scope of this largely qualitative study was limited 
to exploring different approaches to in-market 
distribution and logistics strategies for an off-patent 
blockbuster drug in Spain. It excluded a holistic view 
of the entire end-to-end supply chain including 
sourcing, manufacturing, internal transportation and 
the operational model. In seeking to leverage the 
benefits of the supply chain to obtain a competitive 
urge and drive profitability, a complete look at the 
entire supply chain, particularly the operational 
model, is crucial. In a heavily regulated 
pharmaceutical market like Spain, the result of this 
research helps understand that significant gains 
could be made on the commercial front. Some gains 
could be made from in-market distribution but it 
stands to reason, that the possibility of significant 
gains lie elsewhere which might well serve as good 
grounds for further research. Recommended 
research - preferably quantitative, could delve into 
the manufacturing and operational models of the 
pharmaceutical company to explore areas where it 
could differentiate itself and drive competitive 
advantage. Another area worth investigating would 
be the sourcing strategies and avenues for 
collaboration with other stakeholders. Finally, other 
innovative channels of distribution are gradually 
establishing themselves as viable alternatives. It may 
be early days yet but remote dispensing and mail 
ordering are worth looking into even though the latter 
is not legal in Spain but are allowed in other 
jurisdictions.  
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